Skip to main content
OpenTrials
Completed

NCT Number: NCT03761563

Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease

This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Los Angeles Orthopedic Institute, Sherman Oaks, California, United States

Loading trial locations.

About this study

This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology.

There will be 3 arms in the study, one for each configuration of the Fortilink IBF system (Fortilink-C, Fortilink-TS and Fortilink-L). Up to 50 subjects will be enrolled in each study arm for a total of up to 150 subjects at up to 20 sites in the United States (US) and European Union (EU).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject is skeletally mature and at least 18 years of age.
  • The subject has degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptom at one or two contiguous levels (Fortilink-C), or the subject has DDD and ≤ Grade 1 spondylolisthesis of the lumbar spine at one or two contiguous levels (Fortilink-TS and Fortilink-L).
  • Subject plans to undergo one of the following procedures:

An anterior cervical interbody fusion at one to two continuous levels from C2-C3 to C7-T1 using autogenous or allogenic bone graft and supplemental fixation cleared and indicated for use at the proposed treatment level(s) (Fortilink-C), or

An interbody fusion in the lumbar spine at one to two continuous levels from L1-L2 to L5-S1 using autogenous or allogenic bone graft and supplemental fixation cleared and indicated for use at the proposed treatment level(s) (Fortilink-TS and Fortilink-L).

  • The subject has undergone non-operative treatment of at least six weeks (Fortilink-C) or at least six months (Fortilink-TS and Fortilink-L) prior to treatment with the IBF system.
  • The subject is willing and able to provide informed consent.
  • The subject is willing and able to attend the protocol required follow-up visits and examinations.

Exclusion criteria

  • The subject has an active infection
  • The subject has had prior fusion attempt(s) or is undergoing revision of a previously implanted system at the involved level(s).
  • The subject is a worker's compensation case, in active litigation related to the procedure or is a prisoner or ward of the state.
  • The subject meets one or more of the contraindications outlined in the IFU.
  • The subject is pregnant, nursing, or is planning to become pregnant in the next year.
  • The subject has documented evidence of current substance abuse.
  • The subject has other concurrent medical condition that, in the opinion of the investigator, does not make the subject a good candidate for the study.

Treatment and study plan

Fortilink IBF System with TETRAfuse Technology

Device

Cervical and lumbar fusion

Primary outcomes

  1. Rate of cervical fusion evaluated by radiographic evidence

    Time frame: 12 months

  2. Rate of lumbar fusion evaluated by radiographic evidence

    Time frame: 24 months

Secondary outcomes

  1. Change in pain from baseline evaluated by use of subject-reported 100mm Visual Analogue Scale (VAS)

    Time frame: 1 month, 3 months, 6 months, 12 months, and 24 months

    The VAS pain scale ranges from 0 to 100 where 0 represents No Pain and 100 represents Unbearable Pain.

  2. Radiographic findings by CT evaluation

    Time frame: 12 months and 24 months

  3. Time to return to work

    Time frame: up to 24 months

  4. Incidence of serious device related adverse events

    Time frame: up to 24 months

  5. Incidence of serious procedure related adverse events

    Time frame: up to 24 months

  6. Change in functional ability determined by Neck Disability Index (NDI) or Oswestry Disability Index (ODI)

    Time frame: 3 months, 6 months, 12 months, and 24 months

    The NDI is a subject questionnaire designed to assess neck pain and will only be completed by subjects who undergo cervical implants. The ODI is a subject questionnaire designed to assess back pain and will only be completed by subjects who undergo lumbar implants. Each questionnaire consists of a total score ranging from 0 to 100 where a lower score represents a better outcome and a higher score represents a worse outcome.

  7. Change in quality of life determined by SF-12 questionnaire

    Time frame: 3 months, 6 months, 12 months, and 24 months

    SF-12 questionnaires scores are computed and range from 0 to 100 where a 0 score indicates the lowest level of health and 100 indicates the highest level of health.

  8. Change in pain medication usage from baseline

    Time frame: 1 month, 3 months, 6 months, 12 months, and 24 months

Sponsors and collaborators

Lead sponsor

Xtant Medical

Industry

Registry information

Official study title

Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease (FORTE)

Acronym: FORTE

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Dec 3, 2018
Registry last updated
Mar 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.